Incretin and glucagon levels in adult offspring exposed to maternal diabetes in pregnancy

Journal of Clinical Endocrinology and Metabolism

Volumn 100, Issue 5, 2015, Pages 1967-1975

  Kelstrup, Louise ^a   Clausen, Tine D ^a,b   Mathiesen, Elisabeth R ^a,c   Hansen, Torben ^d,e   Holst, Jens J ^d   Damm, Peter ^a,c  

^a University of Copenhagen   (Denmark)

^b HILLERØD HOSPITAL   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INCRETIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOCHEMICAL ANALYSIS; CONTROLLED STUDY; DENMARK; FEMALE; GENETIC PREDISPOSITION; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; HUMAN; HYPERGLUCAGONEMIA; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; MALE; MATERNAL DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PATHOGENESIS; POSTPRANDIAL STATE; PREGNANCY; PREGNANCY DIABETES MELLITUS; PRIORITY JOURNAL; PROGENY; PROTEIN BLOOD LEVEL; RISK FACTOR; ADOLESCENT; ADULT CHILD; BLOOD; FOLLOW UP; GLUCOSE TOLERANCE TEST; INSULIN DEPENDENT DIABETES MELLITUS; PRENATAL EXPOSURE; YOUNG ADULT;

ADOLESCENT; ADULT; ADULT CHILDREN; DIABETES MELLITUS, TYPE 1; DIABETES, GESTATIONAL; FEMALE; FOLLOW-UP STUDIES; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE TOLERANCE TEST; HUMANS; MALE; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; YOUNG ADULT;

EID: 84929340519     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-3978     Document Type: Article

References (40)

1. Boney CM, Verma A, Tucker R, Vohr BR. Metabolic syndrome in childhood: association with birth weight, maternal obesity, and gestational diabetes mellitus. Pediatrics. 2005;115(3):e290-e296.
2. Clausen TD, Mathiesen ER, Hansen T, et al. High prevalence of type 2 diabetes and pre-diabetes in adult offspring of women with gestational diabetes mellitus or type 1 diabetes: the role of intrauterine hyperglycemia. Diabetes Care. 2008;31(2):340-346.
3. Clausen TD, Mathiesen ER, Hansen T, et al. Overweight and the metabolic syndrome in adult offspring of women with diet-treated gestational diabetes mellitus or type 1 diabetes. J Clin Endocrinol Metab. 2009;94(7):2464-2470.
4. Kelstrup L, Damm P, Mathiesen ER, et al. Insulin resistance and impaired pancreatic β-cell function in adult offspring of women with diabetes in pregnancy. J Clin Endocrinol Metab. 2013;98(9):3793-3801.
5. Freinkel N. Banting Lecture 1980. Of pregnancy and progeny. Diabetes. 1980;29(12):1023-1035.
6. Sobngwi E, Boudou P, Mauvais-Jarvis F, et al. Effect of a diabetic environment in utero on predisposition to type 2 diabetes. Lancet. 2003;361(9372):1861-1865.
7. Dunning BE, Gerich JE. The role of α-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications. Endocr Rev. 2007;28(3):253-283.
8. Holst JJ, Knop FK, Vilsboll T, Krarup T, Madsbad S. Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes. Diabetes Care. 2011;34(suppl 2):S251-S257.
9. Nauck MA, Baller B, Meier JJ. Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes. Diabetes. 2004;53(suppl 3):S190-S196.
10. Reaven GM, Chen YD, Golay A, Swislocki AL, Jaspan JB. Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1987;64(1):106-110.
11. Hampton SM, Morgan LM, Tredger JA, Cramb R, Marks V. Insulin and C-peptide levels after oral and intravenous glucose. Contribution of enteroinsular axis to insulin secretion. Diabetes. 1986;35(5): 612-616.
12. Nauck MA, Homberger E, Siegel EG, et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab. 1986;63(2):492-498.
13. Meier JJ, Hücking K, Holst JJ, Deacon CF, Schmiegel WH, Nauck MA. Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes. Diabetes. 2001;50(11):2497-2504.
14. Nauck MA, El-Ouaghlidi A, Gabrys B, et al. Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes. Regul Pept. 2004;122(3):209-217.
15. Schou JH, Pilgaard K, Vilsbøll T, et al. Normal secretion and action of the gut incretin hormones glucagon-like peptide-1 and glucosedependent insulinotropic polypeptide in young men with low birth weight. J Clin Endocrinol Metab. 2005;90(8):4912-4919.
16. Chandler-Laney PC, Bush NC, Rouse DJ, Mancuso MS, Gower BA. Gut hormone activity of children born to women with and without gestational diabetes. Pediatr Obes. 2014;9(1):53-62.
17. Lauenborg J, Grarup N, Damm P, et al. Common type 2 diabetes risk gene variants associate with gestational diabetes. J Clin Endocrinol Metab. 2009;94(1):145-150.
18. Guttorm E. Practical screening for diabetes mellitus in pregnant women. Acta Endocrinol Suppl (Copenh). 1974;182:11-24.
19. Jensen DM, Mølsted-Pedersen L, Beck-Nielsen H, Westergaard JG, Ovesen P, Damm P. Screening for gestational diabetes mellitus by a model based on risk indicators: a prospective study. Am J Obstet Gynecol. 2003;189(5):1383-1388.
20. Kühl C. Glucose metabolism during and after pregnancy in normal and gestational diabetic women. 1. Influence of normal pregnancy on serum glucose and insulin concentration during basal fasting conditions and after a challenge with glucose. Acta Endocrinol (Copenh). 1975;79(4):709-719.
21. Damm P, Kühl C, Bertelsen A, Mølsted-Pedersen L. Predictive factors for the development of diabetes in women with previous gestational diabetes mellitus. Am J Obstet Gynecol. 1992;167(3): 607-616.
22. Damm P. Gestational diabetes mellitus and subsequent development of overt diabetes mellitus. Dan Med Bull. 1998;45(5):495-509.
23. Matthews JN, Altman DG, Campbell MJ, Royston P. Analysis of serial measurements in medical research. BMJ. 1990;300(6719): 230-235.
24. Christensen U, Lund R, Damsgaard MT, et al. Cynical hostility, socioeconomic position, health behaviors, and symptom load: a cross-sectional analysis in a Danish population-based study. Psychosom Med. 2004;66(4):572-577.
25. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15(7):539-553.
26. Marsál K, Persson PH, Larsen T, Lilja H, Selbing A, Sultan B. Intrauterine growth curves based on ultrasonically estimated foetal weights. Acta Paediatr. 1996;85(7):843-848.
27. Orskov C, Rabenhøj L, Wettergren A, Kofod H, Holst JJ. Tissue and plasma concentrations of amidated and glycine-extended glucagonlike peptide I in humans. Diabetes. 1994;43(4):535-539.
28. Krarup T, Madsbad S, Moody AJ, et al. Diminished immunoreactive gastric inhibitory polypeptide response to a meal in newly diagnosed type I (insulin-dependent) diabetics. J Clin Endocrinol Metab. 1983; 56(6):1306-1312.
29. Lindgren O, Carr RD, Deacon CF, et al. Incretin hormone and insulin responses to oral versus intravenous lipid administration in humans. J Clin Endocrinol Metab. 2011;96(8):2519-2524.
30. Holst JJ. Evidence that enteroglucagon (II) is identical with the C- terminal sequence (residues 33-69) of glicentin. Biochem J. 1982; 207(3):381-388.
31. Wewer Albrechtsen NJ, Hartmann B, Veedfald S, et al. Hyperglucagonaemia analysed by glucagon sandwich ELISA: nonspecific interference or truly elevated levels? Diabetologia. 2014;57:1919-1926.
32. Hansen KB, Vilsbøll T, Bagger JI, Holst JJ, Knop FK. Impaired incretin-induced amplification of insulin secretion after glucose homeostatic dysregulation in healthy subjects. J Clin Endocrinol Metab. 2012;97(4):1363-1370.
33. Knop FK, Vilsbøll T, Højberg PV, et al. Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state? Diabetes. 2007;56(8):1951-1959.
34. Vollmer K, Holst JJ, Baller B, et al. Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance. Diabetes. 2008;57(3):678-687.
35. Toft-Nielsen MB, Damholt MB, Madsbad S, et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab. 2001;86(8):3717-3723.
36. Muscelli E, Mari A, Casolaro A, et al. Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Diabetes. 2008;57(5):1340-1348.
37. Gjesing AP, Ekstrøm CT, Eiberg H, et al. Fasting and oral glucosestimulated levels of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are highly familial traits. Diabetologia. 2012;55(5):1338-1345.
38. Matikainen N, Bogl LH, Hakkarainen A, et al. GLP-1 responses are heritable and blunted in acquired obesity with high liver fat and insulin resistance. Diabetes Care. 2014;37(1):242-251.
39. Saxena R, Hivert MF, Langenberg C, et al. Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. Nat Genet. 2010;42(2):142-148.
40. Speliotes EK, Willer CJ, Berndt SI, et al. Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet. 2010;42(11):937-948.